Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Review

Epidemiology of Sanfilippo syndrome: results of a systematic literature review

Authors: Tamás Zelei, Kata Csetneki, Zoltán Vokó, Csaba Siffel

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Sanfilippo syndrome (mucopolysaccharidosis [MPS] III subtypes A, B, C, and D) is a rare autosomal recessive inherited metabolic disorder that causes progressive neurocognitive degeneration. This systematic literature review was undertaken to compile and assess published epidemiological data, including various frequency measures and geographical variation on Sanfilippo syndrome.

Methods

The following databases were systematically searched for terms related to Sanfilippo syndrome epidemiology: Medline, Embase, Cochrane Database of Systematic Reviews, Academic Search Complete, Cumulative Index to Nursing and Allied Health Literature, and the Centre for Reviews and Dissemination. Qualitative synthesis of research findings was performed.

Results

Of 2794 publications found in the initial search, 116 were deemed eligible after title and abstract screening. Following full-text review, 46 papers were included in the qualitative synthesis. Results of this systematic literature review indicate that lifetime risk at birth ranges from 0.17–2.35 per 100,000 live births for all 4 subtypes of MPS III together, and from 0.00–1.62 per 100,000 live births for the most frequent subtype, MPS IIIA.

Conclusion

All 4 subtypes of MPS III are exceptionally rare, but they each have devastating effects on children. Higher-quality epidemiological data are needed to appropriately target resources for disease research and management.
Appendix
Available only for authorised users
Literature
1.
Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis. 2008;31:240–52.CrossRefPubMed
2.
3.
4.
5.
6.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral
7.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8.CrossRefPubMedPubMedCentral
8.
Bodamer OA, Giugliani R, Wood T. The laboratory diagnosis of mucopolysaccharidosis III (Sanfilippo syndrome): a changing landscape. Mol Genet Metab. 2014;113:34–41.CrossRefPubMed
9.
Foss AH, Duffner PK, Carter RL. Lifetime risk estimators in epidemiological studies of Krabbe disease: review and Monte Carlo comparison. Rare Dis. 2013;1:e25212.CrossRefPubMedPubMedCentral
10.
Hutchesson AC, Bundey S, Preece MA, Hall SK, Green A. A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK. J Med Genet. 1998;35:366–70.CrossRefPubMedPubMedCentral
11.
Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics. 2000;105:e10.CrossRefPubMed
12.
Malm G, Lund AM, Månsson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97:1577–81.CrossRefPubMed
13.
Poupetová H, Ledvinová J, Berná L, Dvoráková L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33:387–96.CrossRefPubMedPubMedCentral
14.
Ben Turkia H, Tebib N, Azzouz H, Abdelmoula MS, Ben Chehida A, Chemli J, et al. Incidence of mucopolysaccharidoses in Tunisia. Tunis Med. 2009;87:782–5.PubMed
15.
Al-Maawali AA, Joshi SN, Koul RL, Al-Sedari HS, Al-Amri BM, Al-Futaisi AM. Spectrum of paediatric lysosomal storage disorders in Oman. Sultan Qaboos Univ Med J. 2012;12:295–9.CrossRefPubMedPubMedCentral
16.
Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy. 2015;119:964–79.CrossRefPubMed
17.
Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28:1011–7.CrossRefPubMed
18.
Gómez AM, García-Robles R, Suárez-Obando F. Estimation of the mucopolysaccharidoses frequencies and cluster analysis in the Colombian provinces of Cundinamarca and Boyaca [in Spanish]. Biomedica. 2012;32:602–9.CrossRefPubMed
19.
Héron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, et al. Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. Am J Med Genet A. 2011;155A:58–68.CrossRefPubMed
20.
Hult M, Darin N, von Döbeln U, Månsson JE. Epidemiology of lysosomal storage diseases in Sweden. Acta Paediatr. 2014;103:1258–63.CrossRefPubMed
21.
Joshi SN, Hashim J, Venugopalan P. Pattern of inborn errors of metabolism in an Omani population of the Arabian peninsula. Ann Trop Paediatr. 2002;22:93–6.CrossRefPubMed
22.
Jurecka A, Ługowska A, Golda A, Czartoryska B, Tylki-Szymańska A. Prevalence rates of mucopolysaccharidoses in Poland. J Appl Genet. 2015;56:205–10.CrossRefPubMed
23.
Lin H-Y, Lin S-P, Chuang C-K, Niu D-M, Chen M-R, Tsai F-J, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am J Med Genet A. 2009;149A:960–4.CrossRefPubMed
24.
Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. Ann Saudi Med. 2010;30:271–7.CrossRefPubMedPubMedCentral
25.
26.
Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A:310–3.CrossRefPubMed
27.
Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12:87–92.CrossRefPubMed
28.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet. 1999;105:151–6.CrossRefPubMed
29.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.CrossRefPubMed
30.
Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Hertecant JL, Bastaki F, et al. Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates: LSD in UAE. JIMD Rep. 2013;10:1–9.PubMedPubMedCentral
31.
Krabbi K, Joost K, Zordania R, Talvik I, Rein R, Huijmans JG, et al. The live-birth prevalence of mucopolysaccharidoses in Estonia. Genet Test Mol Biomarkers. 2012;16:846–9.CrossRefPubMedPubMedCentral
32.
Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, et al. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr. 2002;140:321–7.CrossRefPubMed
33.
Lowry RB, Applegarth DA, Toone JR, MacDonald E, Thunem NY. An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet. 1990;85:389–90.CrossRefPubMed
34.
Church H, Petty J, Righart J, Parkes O, Egerton C, Savage W, et al. The incidence of mucopolysaccharidoses and related disorders in the Turkish population: a 3 year study. Mol Genet Metab. 2013;108:S30.CrossRef
35.
Coelho JC, Wajner M, Burin MG, Vargas CR, Giugliani R. Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. Eur J Pediatr. 1997;156:650–4.CrossRefPubMed
36.
37.
Emre S, Terzioğlu M, Coşkun T, Tokath A, Ozalp I, Müller V, et al. Biochemical and molecular analysis of mucopolysaccharidoses in Turkey. Turk J Pediatr. 2002;44:13–7.PubMed
38.
39.
Ozand PT, Devol EB, Gascon GG. Neurometabolic diseases at a national referral center: five years experience at the King Faisal Specialist Hospital and Research Centre. J Child Neurol. 1992;7(Suppl):S4–11.CrossRefPubMed
40.
Sewell AC. Urinary screening for disorders of heteroglycan metabolism: results of 10 years experience with a comprehensive system. Klin Wochenschr. 1988;66:48–53.CrossRefPubMed
41.
Kadali S, Kolusu A, Gummadi MR, Undamatia J. The relative frequency of lysosomal storage disorders: a medical genetics referral laboratory's experience from India. J Child Neurol. 2014;29:1377–82.CrossRefPubMed
42.
Krasnopolskaya XD, Mirenburg TV, Akhunov VS, Voskoboeva EY. Postnatal and prenatal diagnosis of lysosomal storage diseases in the former Soviet Union. Wien Klin Wochenschr. 1997;109:74–80.PubMed
43.
Kagalwala TY, Bharucha BA, Kumta NB, Naik GG. The mucopolysaccharidoses: a study of 48 cases. Indian J Pediatr. 1988;55:919–25.CrossRefPubMed
44.
Michelakakis H, Dimitriou E, Tsagaraki S, Giouroukos S, Schulpis K, Bartsocas CS. Lysosomal storage diseases in Greece. Genet Couns. 1995;6:43–7.PubMed
45.
LeBowitz JH, Wyatt T, Clark G, Yu K, Aoyagi-Scharber M. Utilizing activity assays and population-wide allele frequencies to assess the contribution of novel mutations in NAGLU to MPS IIIB incidence. Mol Genet Metab. 2016;117:S72.CrossRef
46.
Menéndez-Sainz C, Gonzaléz-García S, Peña-Sánchez M, Zaldívar-Muñoz C, González-Quevedo A. Mucopolysaccharidosis: 20-year enzymatic diagnosis in Cuba [in Spanish]. Rev Neurol. 2009;49:458–62.PubMed
47.
Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter G, Wevers R, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010;68:876–87.CrossRefPubMed
48.
Ruijter GJ, Valstar MJ, van de Kamp JM, van der Helm RM, Durand S, van Diggelen OP, et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in the Netherlands. Mol Genet Metab. 2008;93:104–11.CrossRefPubMed
49.
van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet. 1981;20:152–60.CrossRefPubMed
50.
Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121:227–40.CrossRefPubMed
Metadata
Title
Epidemiology of Sanfilippo syndrome: results of a systematic literature review
Authors
Tamás Zelei
Kata Csetneki
Zoltán Vokó
Csaba Siffel
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0796-4

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue

Research

Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism

Research

A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era

Research

The patient journey to diagnosis and treatment of autoinflammatory diseases

Research

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

Research

The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome

Research

Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study